Reuters logo
BRIEF-Pfizer says ‍results indicated a improvement in OS for patients
September 11, 2017 / 11:33 AM / 11 days ago

BRIEF-Pfizer says ‍results indicated a improvement in OS for patients

Sept 11 (Reuters) - Pfizer Inc:

* Pfizer Inc - ‍results indicated a numerical improvement in OS for patients treated with first-line xalkori compared with chemotherapy​

* ‍Pfizer presents overall survival data of xalkori in patients with ALK-positive advanced non-small cell lung cancer​

* Pfizer Inc - ‍after a median follow-up of 46 months, median OS for patients randomized to xalkori was not reached​

* Pfizer Inc -‍ the difference of the numerical improvement​ “did not quite achieve statistical significance ”

* Pfizer - 84 percent of patients initially randomized to chemotherapy received xalkori after they progressed, this likely affected overall survival results​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below